Stockscreener 앱 받기
7.68
0.13%
-0.01
시간 외 거래:
7.68
Aura Biosciences Inc 주식(AURA)의 최신 뉴스
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell - MarketBeat
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap - Stock Titan
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
HC Wainwright Raises Earnings Estimates for Aura Biosciences - MarketBeat
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person - Stock Titan
Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report - Stock Titan
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3 - Stock Titan
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24 - webull.com
Aura refocuses clinical plans, reduces staff by 20% - The Business Journals
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control - Stock Titan
Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - marketbeat.com
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Nigeria
Analysts Offer Predictions for AURA Q1 Earnings - marketbeat.com
Aura BiosciencesMay Offer Securities Up To $500 Million Aggregate - TradingView
Aura Biosciences (NASDAQ: AURA) sets $500M shelf and $200M ATM - stocktitan.net
Aura Biosciences Releases Q2 2026 Financial Results - AlphaStreet
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - marketbeat.com
Aura Biosciences Extends Cash Runway Into First Half 202 - Minichart
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount - stocktitan.net
Aura Biosciences Q2 Loss Widens - marketscreener.com
Aura Biosciences Restructures, Refocuses on Ocular Oncology - tipranks.com
Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary - TradingView
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
AURA: Q2 net loss widened to $45.6M; $280.8M raised, restructuring shifts focus to ocular oncology - TradingView
Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss - Quiver Quantitative
AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029 - TradingView
Aura Biosciences, Inc. Announces Executive Changes - marketscreener.com
Layoff Tracker: Aura, Schrödinger trim workforces - BioSpace
Responsive Playbooks and the AURA Inflection - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) Raised to Hold at Wall Street Zen - MarketBeat
Aura Biosciences Expands Authorized Shares and Incentive Plan - TipRanks
Aura Biosciences (AURA) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
AURA Q2'26 Earnings: EPS estimate is (0.38) USD - TradingView
InvestingPro Fair Value predicted Aura Biosciences’ 40% decline By Investing.com - Investing.com Nigeria
Aura Biosciences, Inc. Revenue Breakdown – NASDAQ:AURA - TradingView
AURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Understanding the Setup: (AURA) and Scalable Risk - Stock Traders Daily
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AURA|Aura Biosciences Inc|Price:7.155|Chg%:+0.105 - TradingKey
BlackRock (AURA holder) discloses 4.4% Aura Biosciences stake in amended filing - Stock Titan
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aura Biosciences Inc (AURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AURA|Aura Biosciences Inc|Price:7.050|Chg%:-0.150 - TradingKey
Aura Biosciences Inc (AURA) Cash Flow - TradingKey
Aura Biosciences Inc (AURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aura Biosciences Inc (AURA) Income Statement - TradingKey
Aura Biosciences Inc (AURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aura Biosciences, Inc. Revenue Breakdown – BOATS:AURA - TradingView
Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing Potential - TipRanks
The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily
Price to earnings forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Price to book forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Enterprise value to revenue forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Enterprise value to EBITDA forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Price to sales forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Aura Biosciences (AURA) Slips 2.3% as Stock Tests Key Support Near $6.50Synthetic Short - dars.gov.et
Form 4 Aura Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
1.80%
1.77%
자본화:
|
볼륨(24시간):